BeiGene Ltd.
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 139
- Registration Number
- NCT03150810
- Locations
- 🇺🇸
Start Midwest, Grand Rapids, Michigan, United States
🇺🇸Washington University in St Louis, Saint Louis, Missouri, United States
🇺🇸Montefiore Medical Park At Eastchester Einstein Campus, Bronx, New York, United States
Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 41
- Registration Number
- NCT03145064
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 201
- Registration Number
- NCT03053440
- Locations
- 🇺🇸
Mayo Clinic Phoenix, Phoenix, Arizona, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 75
- Registration Number
- NCT02795182
- Locations
- 🇦🇺
St Vincent's Hospital, Darlinghurst, New South Wales, Australia
🇨🇳Guangdong General Hospital, Guangzhou, Guangdong, China
🇦🇺Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 229
- Registration Number
- NCT02660034
- Locations
- 🇦🇺
Prince of Wales, Randwick, New South Wales, Australia
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇬🇧Sarah Cannon Research Institute, London, United Kingdom
Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 131
- Registration Number
- NCT02610361
- Locations
- 🇦🇺
Chris Obrien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺North Coast Cancer Institute, Macquarie, New South Wales, Australia
🇦🇺Box Hill Hospital, Box Hill, Victoria, Australia
BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
- Conditions
- B-cell Lymphoid Malignancies
- Interventions
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 119
- Registration Number
- NCT02569476
- Locations
- 🇺🇸
Florida Cancer Specialists Fort Myers, Fort Myers, Florida, United States
🇺🇸Florida Cancer Specialists East, West Palm Beach, Florida, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors
- Conditions
- Advanced Cancer
- Interventions
- Biological: BGB-A317
- First Posted Date
- 2015-04-03
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 451
- Registration Number
- NCT02407990
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇦🇺Austin Health Hospital, Heidelberg, Victoria, Australia
🇦🇺Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
Phase 1a/1b BGB-290 for Advanced Solid Tumors.
- Conditions
- For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment
- Interventions
- First Posted Date
- 2015-02-12
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 101
- Registration Number
- NCT02361723
- Locations
- 🇦🇺
Cancer Care Wollongong, Wollongong, New South Wales, Australia
🇦🇺Gosford Hospital, Gosford, New South Wales, Australia
🇦🇺Flinders Medical Centre, Bedford PK, South Australia, Australia
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 385
- Registration Number
- NCT02343120
- Locations
- 🇦🇺
St George Hospital, Sydney, New South Wales, Australia
🇦🇺Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇦🇺Peter MacCallum Cancer Centre, East Melbourne, Parkville, Victoria, Australia